Edesa Biotech Announces Upcoming Conference Schedule

About this update from Edesa Biotech, Inc.

[{"type":"image","alt":"Edesa Biotech, Inc.","displaySize":"","headline":null,"caption":"Edesa Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/437f565f3f5588d6751519b1f57c6845"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t.5EqO96_gAvHppjoVLQxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/437f565f3f5588d6751519b1f57c6845","width":300,"height":157}},"lazy":false},{"type":"text","content":"TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences:","length":331,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BIO-Europe, Vienna, Austria, November 3-5, 2025","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"LSX Investival Showcase Europe, London, UK, November 17, 2025. Presentation at 3:45 pm GMT.","length":91,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":138,"olType":false},{"type":"text","content":"To schedule a meeting with Edesa during the events, please contact conference organizers or the company directly at [email protected].","length":143,"tagName":"p"},{"type":"text","content":"About Edesa Biotech, Inc.","length":25,"tagName":"p"},{"type":"text","content":"Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company’s most advanced Respiratory drug candidate is paridiprubart, which is being developed as a potential treatmen...

More updates from Edesa Biotech, Inc.